Skip to navigation Skip to content

Solid tumours with confirmed NTRK gene fusion Program in Pharmaceutical Benefits Scheme (PBS) 012-22062457

Expand/Collapse all sectionsExpand all


This document outlines details of PBS-subsidised larotrectinib for patients with solid tumours with confirmed neurotrophic tropomyosin receptor kinase (NTRK) gene fusion.

For information on how to process a PBS Authority, see Processing Complex Authority Required Listings.

Solid tumours with confirmed NTRK gene fusion quick reference

Restrictions

Authority level and section

PA assessment

Processing system

Prescriber type

Prescriber self-serve

Initial

PB333 form

Written

Electronic

S85:

larotrectinib

No

OPA

Not specified

Yes

Continuing

Telephone

Electronic

S85:

larotrectinib

No

OPA

Not specified

Yes